| 2022-08-25 |
详情>>
业绩披露：
2022年中报每股收益0.90元,归母净利润254.16亿元,同比去年增长-37.97%
|
| 2022-08-15 |
股东大会：
将于2022-09-21召开股东大会
会议内容 ▼▲
- 1.To consider and approve the election of Mr. Zhao Peng as an Executive Director of the seventh session of the Board of Directors of the Company.
2.To consider and approve the Company’s investment in Xincheng Phase II Fund.
|
| 2022-05-25 |
股东大会：
将于2022-06-29召开股东大会
会议内容 ▼▲
- 1.To consider and approve the report of the Board of Directors of the Company for the year 2021.
2.To consider and approve the report of the Board of Supervisors of the Company for the year 2021.
3.To consider and approve the financial report of the Company for the year 2021.
4.To consider and approve the profit distribution plan of the Company for the year 2021.
5.To consider and approve the remuneration of Directors and Supervisors of the Company.
6.To receive the duty report of the Independent Directors of the Company for the year 2021.
7.To receive the report on the overall status of connected transactions of the Company for the year 2021.
8.To consider and approve the appointment of auditors of the Company for the year 2022.
|
| 2022-04-29 |
详情>>
业绩披露：
2021年年报每股收益1.80元,归母净利润509.21亿元,同比去年增长1.30%
|
| 2022-04-27 |
详情>>
业绩披露：
2022年一季报每股收益0.54元,归母净利润151.78亿元,同比去年增长-46.91%
|
| 2021-10-28 |
详情>>
业绩披露：
2021年三季报(累计)每股收益1.72元,归母净利润485.02亿元,同比去年增长3.02%
|
| 2021-09-28 |
股东大会：
将于2021-12-16召开股东大会
会议内容 ▼▲
- 1.To consider and approve the proposed amendments to the Procedural Rules for the Shareholders’ General Meetings (the full text of which is set out in Appendix II to the circular of the Company dated 29 September 2021 (the “Circular”)), and to authorize the Chairman of the Board of Directors or any person(s) authorized by him to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
2.To consider and approve the proposed amendments to the Procedural Rules for the Board of Directors’ Meetings (the full text of which is set out in Appendix III to the Circular), and to authorize the Chairman of the Board of Directors or any person(s) authorized by him to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
3.To consider and approve the proposed amendments to the Articles of Association (the full text of which is set out in Appendix I to the Circular), and to authorize the Chairman of the Board of Directors or any person(s) authorized by him to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-25 |
详情>>
业绩披露：
2021年中报每股收益1.45元,归母净利润409.75亿元,同比去年增长34.19%
|
| 2021-05-25 |
股东大会：
将于2021-06-30召开股东大会
会议内容 ▼▲
- 1.To consider and approve the report of the Board of Directors of the Company for the year 2020.
2.To consider and approve the report of the Board of Supervisors of the Company for the year 2020.
3.To consider and approve the financial report of the Company for the year 2020.
4.To consider and approve the profit distribution plan of the Company for the year 2020.
5.To consider and approve the remuneration of Directors and Supervisors of the Company.
6.To consider and approve the election of Mr. Wang Bin as an Executive Director of the seventh session of the Board of Directors of the Company.
7.To consider and approve the election of Mr. Su Hengxuan as an Executive Director of the seventh session of the Board of Directors of the Company.
8.To consider and approve the election of Mr. Li Mingguang as an Executive Director of the seventh session of the Board of Directors of the Company.
9.To consider and approve the election of Ms. Huang Xiumei as an Executive Director of the seventh session of the Board of Directors of the Company.
10.To consider and approve the election of Mr. Yuan Changqing as a Non-executive Director of the seventh session of the Board of Directors of the Company.
11.To consider and approve the election of Mr. Wu Shaohua as a Non-executive Director of the seventh session of the Board of Directors of the Company.
12.To consider and approve the election of Mr. Sheng Hetai as a Non-executive Director of the seventh session of the Board of Directors of the Company.
13.To consider and approve the election of Mr. Wang Junhui as a Non-executive Director of the seventh session of the Board of Directors of the Company.
14.To consider and approve the election of Mr. Tang Xin as an Independent Director of the seventh session of the Board of Directors of the Company.
15.To consider and approve the election of Ms. Leung Oi-Sie Elsie as an Independent Director of the seventh session of the Board of Directors of the Company.
16.To consider and approve the election of Mr. Lam Chi Kuen as an Independent Director of the seventh session of the Board of Directors of the Company.
17.To consider and approve the election of Mr. Zhai Haitao as an Independent Director of the seventh session of the Board of Directors of the Company.
18.To consider and approve the election of Mr. Jia Yuzeng as a Non-employee Representative Supervisor of the seventh session of the Board of Supervisors of the Company.
19.To consider and approve the election of Mr. Han Bing as a Non-employee Representative Supervisor of the seventh session of the Board of Supervisors of the Company.
20.To consider and approve the election of Mr. Niu Kailong as a Non-employee Representative Supervisor of the seventh session of the Board of Supervisors of the Company.
21.To consider and approve the renewal by the Company of liability insurance for Directors, Supervisors and senior management.
22.To consider and approve the continued donations by the Company to China Life Foundation.
23.To consider and approve the appointment of auditors of the Company for the year 2021, and to authorize the Board of Directors to determine their remuneration.
24.To authorize the Board of Directors to determine if the Company shall issue overseas listed foreign shares (“H Shares”), after taking into account the market conditions and the needs of the Company, of an amount of not more than 20% of the H Shares of the Company in issue as at the date of passing of the special resolution at the Annual General Meeting.
|
| 2021-04-29 |
详情>>
业绩披露：
2020年年报每股收益1.77元,归母净利润502.68亿元,同比去年增长-13.76%
|
| 2021-04-28 |
详情>>
业绩披露：
2021年一季报每股收益1.01元,归母净利润285.89亿元,同比去年增长67.28%
|
| 2020-10-28 |
详情>>
业绩披露：
2020年三季报(累计)每股收益1.66元,归母净利润470.78亿元,同比去年增长-18.41%
|
| 2020-08-26 |
详情>>
业绩披露：
2020年中报每股收益1.07元,归母净利润305.35亿元,同比去年增长-18.79%
|
| 2020-04-29 |
详情>>
业绩披露：
2019年年报每股收益2.05元,归母净利润582.87亿元,同比去年增长411.51%
|
| 2020-04-16 |
股东大会：
将于2020-06-29召开股东大会
会议内容 ▼▲
- ORDINARY RESOLUTIONS
1.To consider and approve the report of the Board of Directors of the Company for the year 2019.
2.To consider and approve the report of the Board of Supervisors of the Company for the year 2019.
3.To consider and approve the financial report of the Company for the year 2019.
4.To consider and approve the profit distribution plan of the Company for the year 2019.
5.To consider and approve the remuneration of Directors and Supervisors of the Company.
6.To consider and approve the election of Mr. Lam Chi Kuen as an Independent Director of the sixth session of the Board of Directors of the Company.
7.To consider and approve the remuneration of auditors of the Company for the year 2019 and the appointment of auditors of the Company for the year 2020.
SPECIAL RESOLUTION
8.To authorize the Board of Directors to determine if the Company shall issue overseas listed foreign shares (“H Shares”), after taking into account the market conditions and the needs of the Company, of an amount of not more than 20% of the H Shares of the Company in issue as at the date of passing of the special resolution at the Annual General Meeting.
TO RECEIVE RELEVANT REPORTS
9.To receive the duty report of the Independent Directors of the Board of Directors of the Company for the year 2019.
10.To receive the report on the overall status of connected transactions of the Company for the year 2019.
|
| 2020-01-02 |
股东大会：
将于2020-02-20召开股东大会
会议内容 ▼▲
- ORDINARY RESOLUTIONS
1.To consider and approve the investment by the Company in China Life Aged-care Industry Investment Fund.
|
| 2019-10-31 |
股东大会：
将于2019-12-19召开股东大会
会议内容 ▼▲
- ORDINARY RESOLUTIONS
1.To consider and approve the election of Mr. Zhao Peng as an Executive Director of the sixth session of the Board of Directors of the Company.
2.To consider and approve the proposed amendments to the Procedural Rules for the Board of Directors’ Meetings, and to authorize the Chairman of the Board of Directors or any person(s) authorized by him to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
3.To consider and approve the renewal of continuing connected transactions with China Life AMP Asset Management Co., Ltd.:
3.1To consider and approve the Company Framework Agreement (as defined and described in the circular to be despatched by the Company to the shareholders (the “Circular”)) and the Pension Company Framework Agreement (as defined and described in the Circular), the transactions contemplated thereunder and the annual caps for the three years ending 31 December 2022 relating thereto;
3.2To consider and approve the CLIC Framework Agreement (as defined and described in the Circular), the CLP&C Framework Agreement (as defined and described in the Circular) and the CLI Framework Agreement (as defined and described in the Circular), the transactions contemplated thereunder and the annual caps for the three years ending 31 December 2022 relating thereto.
4.To consider and approve the renewal of the Framework Agreement for Daily Connected Transactions between the Company and China Guangfa Bank Co., Ltd.
SPECIAL RESOLUTION
5.To consider and approve the proposed amendments to the Articles of Association, and to authorize the Chairman of the Board of Directors or any person(s) authorized by him to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
|
| 2019-04-11 |
股东大会：
将于2019-05-30召开股东大会
会议内容 ▼▲
- ORDINARY RESOLUTIONS
1.To consider and approve the report of the Board of Directors of the Company for the year 2018.
2.To consider and approve the report of the Board of Supervisors of the Company for the year 2018.
3.To consider and approve the financial report of the Company for the year 2018.
4.To consider and approve the profit distribution plan of the Company for the year 2018.
5.To consider and approve the remuneration of Directors and Supervisors of the Company.
6.To consider and approve the election of Mr. Han Bing as a Non-employee Representative Supervisor of the six session of the Board of Supervisors of the Company.
7.To consider and approve the proposed amendments to the Procedural Rules for the Shareholders’ General Meetings (the full text of which is set out in Appendix III to the circular of the Company dated 12 April 2019 (the “Circular”)), and to authorize the Chairman of the Board of Directors or any person(s) authorized by him to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
8.To consider and approve the proposed amendments to the Procedural Rules for the Board of Directors’ Meetings (the full text of which is set out in Appendix IV to the Circular), and to authorize the Chairman of the Board of Directors or any person(s) authorized by him to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
9.To consider and approve the proposed amendments to the Procedural Rules for the Board of Supervisors’ Meetings (the full text of which is set out in Appendix V to the Circular), and to authorize the Chairman of the Board of Supervisors or any person(s) authorized by him to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
10.To consider and approve the remuneration of auditors of the Company for the year 2018 and the appointment of auditors of the Company for the year 2019.
SPECIAL RESOLUTIONS
11.To consider and approve the proposed amendments to the Articles of Association (the full text of which is set out in Appendix II to the Circular), and to authorize the Chairman of the Board of Directors or any person(s) authorized by him to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
12.To authorize the Board of Directors to determine if the Company shall issue overseas listed foreign shares (“H Shares”), after taking into account the market conditions and the needs of the Company, of an amount of not more than 20% of the H Shares of the Company in issue as at the date of passing of the special resolution at the Annual General Meeting.
Particulars of the authorization include but are not limited to:
(1)To authorize the Board of Directors to allot, issue and deal with H Shares (“New Shares”) in accordance with the Company Law of the PRC and the regulatory requirements of the jurisdictions in which the shares of the Company are listed, after obtaining the approvals of the China Securities Regulatory Commission and other relevant PRC governmental departments. The aggregate nominal value of the New Shares to be allotted and issued (whether pursuant to a share option or otherwise) shall not exceed 20% of the total nominal value of the H Shares of the Company in issue as at the date of passing of this resolution.
(2)To authorize the Board of Directors to exercise the power of the Company to determine the terms and conditions for the allotment and issue of the New Shares, which include but not limited to:
(a)the class and number of the New Shares to be allotted and/or issued;
(b)the target of the issue and the use of proceeds;
(c)the method of determining the issue price of the New Shares and/or the issue price (including the price range);
(d)the commencement and closing dates for the issue;
(e)the class and number of the New Shares to be issued to the existing shareholders;
(f)the making or grant of offers for sale, agreements and options which may require the exercise of such powers.
(3)To authorize the Board of Directors to execute all necessary documents, to complete the necessary formalities and to take other necessary steps in order to complete the allotment, issue and listing of the New Shares, provided that there is no violation of the relevant laws, administrative regulations, the regulatory requirements of the jurisdictions in which the shares of the Company are listed and the Articles of Association of the Company, including but not limited to:
(a)to consider, approve and execute on behalf of the Company agreements in relation to the issue, such as the underwriting agreement and engagement letters of intermediaries;
(b)to fulfill the relevant approval process according to the requirements of the regulatory authorities and the jurisdictions in which the shares of the Company are listed, and to consider, approve and execute on behalf of the Company legal documents in relation to the issue which shall be submitted to the relevant regulatory authorities;
(c)to amend the relevant agreements and legal documents mentioned in (a) and (b) above in accordance with the requirements of domestic and foreign regulatory authorities;
(d)to consider and approve the affixing of the company seal on the relevant agreements and legal documents;
(e)to engage intermediaries for the issue, and to approve and execute such acts, deeds and documents as may be necessary, appropriate, desirable or relevant for the issue.
(4)To authorize the Board of Directors to, subject to the approval of the relevant PRC authorities, increase the registered capital of the Company to the required amount according to the actual shareholding structure of the Company at the time of completion of the allotment and issue of the New Shares and in accordance with the Company Law of the PRC.
(5)To authorize the Board of Directors to make amendments to the Articles of Association of the Company as appropriate and necessary upon the allotment and issue of the New Shares, according to the method of the allotment and issue of the New Shares of the Company, the type and number of the New Shares to be allotted and issued, and the actual shareholding structure of the Company at the time of completion of the allotment and issue of the New Shares, in order to reflect the changes in the share capital structure and the registered capital of the Company, and any other changes caused by this authorization.
(6)The general mandate shall come into force as of the date of passing of this resolution at the Annual General Meeting and shall continue in force until the earliest of the following three dates:
(a)the conclusion of the annual general meeting of the Company for the year 2019;
(b)the expiration of the 12-month period following the passing of this resolution at the Annual General Meeting;
(c)the date on which the authority given under this resolution is revoked or varied by a special resolution of the shareholders of the Company in a general meeting.
13.To consider and approve the overseas issue of senior bonds in one or more tranche(s) in an aggregate amount of not exceeding USD3 billion or its equivalent in other foreign currency in the next three years based on the capital needs of the Company, the regulatory requirements and the market conditions, and to authorize the Board of Directors to delegate the management of the Company to deal with and decide on all specific matters relating to the overseas issue of such senior bonds, subject to the approval of regulatory authorities and based on the market conditions. Such authorization shall include but not limited to the following:
(1)submitting and reporting to, filing and registering with, obtaining approvals and consents from the relevant domestic or overseas governmental departments and/or regulatory authorities, and undergoing other formalities such as collection of proceeds;
(2)executing, implementing, revising, supplementing, completing, delivering and issuing all relevant agreements, contracts and documents (including, without limitation, announcements, circulars, sponsor and underwriting agreements, and contracts for intermediary service, etc.) in connection with the overseas issue of senior bonds to be submitted to the relevant domestic and overseas regulatory authorities, stock exchanges, organizations and/or individuals;
(3)formulating and implementing a detailed proposal with respect to the overseas issue of senior bonds as well as funds management, including, without limitation, the type of the issue, the size of each tranche, the form of the issue, the timing of the issue, the place of the issue, the tranches, the terms and conditions of the issue, the term of the debts, the coupon rate, the coupon payments, the registration of overseas senior bonds for custody purpose, the measures for the administration of overseas senior bonds, the detailed implementation plan for investment and management of proceeds, the investment manager and guideline, and after taking into account the actual circumstances, market conditions, policy changes and opinions from regulatory departments and domestic and overseas stock exchanges, making necessary changes to the overseas issue of senior bonds and determining the timing of the issue;
(4)the authorization for the overseas issue of senior bonds will be valid for 36 months from the date of approval by the shareholders’ general meeting;
(5)the scheduled payment of interest or dividends accrued and the subsequent repayment of principal in connection with such overseas senior bonds shall be administered in the day-to-day work of the Company according to the requirements of relevant national regulations.
TO RECEIVE RELEVANT REPORTS
14.To receive the duty report of the Independent Directors of the Board of Directors of the Company for the year 2018.
15.To receive the report on the status of connected transactions and the execution of connected transactions management system of the Company for the year 2018.
|
| 2019-02-28 |
详情>>
内部人交易：
GERARD STEVEN L股份增加338.00股
|
| 2018-09-27 |
股东大会：
将于2018-11-13召开股东大会
会议内容 ▼▲
- ORDINARY RESOLUTIONS
1.To consider and approve the election of Mr. Wang Bin as an Executive Director of the sixth session of the Board of Directors of the Company.
2.To consider and approve the election of Mr. Tang Yong as a Non-employee Representative Supervisor of the sixth session of the Board of Supervisors of the Company.
3.To consider and approve the remuneration of Directors and Supervisors of the Company for the year 2017.
SPECIAL RESOLUTION
4.To consider and approve the domestic and overseas multiple issue of debt instruments for replenishment of capital in an aggregate amount of not exceeding RMB80 billion or its equivalent in foreign currency, subject to the Company’s solvency and market conditions. All proceeds from the domestic and overseas issue of such debt instruments for replenishment of capital will, after deduction of the issue expenses, be used to replenish the Company’s capital so as to enhance its solvency.
To authorize the Board of Directors who may delegate the management of the Company to deal with and decide on all specific matters relating to the domestic and overseas issue of such debt instruments for replenishment of capital, subject to the approval of regulatory authorities and based on the market conditions. Such authorization shall include but not be limited to the following:
4.1submitting and reporting to, filing and registering with, obtaining approvals and consents from the relevant domestic or overseas governmental departments and/or regulatory authorities, and undergoing other formalities such as collection of proceeds;
4.2executing, implementing, revising, supplementing, completing, delivering and issuing all relevant agreements, contracts and documents (including, without limitation, announcements, circulars, sponsorship and underwriting agreements, and contracts for intermediary service, etc.) in connection with the domestic and overseas issue of debt instruments for replenishment of capital to the relevant domestic and overseas regulatory authorities, stock exchanges, organizations and/or individuals;
4.3formulating and implementing a detailed proposal with respect to the domestic and overseas issue of debt instruments for replenishment of capital as well as funds management, including, without limitation, the type of the issue, the size of each tranche, the form of the issue, the timing of the issue, the place of the issue, the tranches, the terms and conditions of the issue, the term of the debts, the coupon rate, the coupon payments, the registration of debt instruments for custody purpose, the measures for the administration of domestic and overseas debt instruments for replenishment of capital, the detailed implementation plan for investment and management of proceeds, the selection of investment managers and the formulation of investment guidelines, and after taking into account the actual circumstances, market conditions, policy changes and opinions from regulatory departments and domestic and overseas stock exchanges, making necessary changes to the domestic and overseas issue of debt instruments for replenishment of capital and determining the timing of the issue;
4.4the authorization for the domestic and overseas issue of debt instruments for replenishment of capital will be valid for 36 months from the date of approval by the shareholders’ general meeting;
4.5the scheduled payment of interest or dividends accrued and the subsequent repayment of principal in connection with such debt instruments for replenishment of capital shall be administered in the day-to-day work of the Company according to the relevant laws and regulations.
|
| 2018-04-11 |
股东大会：
将于2018-06-06召开股东大会
会议内容 ▼▲
- ORDINARY RESOLUTIONS
1.To consider and approve the report of the Board of Directors of the Company for the year 2017.
2.To consider and approve the report of the Supervisory Committee of the Company for the year 2017.
3.To consider and approve the financial report of the Company for the year 2017.
4.To consider and approve the profit distribution plan of the Company for the year 2017.
5.To consider and approve the remuneration of Directors and Supervisors of the Company.
6.To consider and approve the election of Mr. Yang Mingsheng as an Executive Director of the sixth session of the Board of Directors of the Company.
7.To consider and approve the election of Mr. Lin Dairen as an Executive Director of the sixth session of the Board of Directors of the Company.
8.To consider and approve the election of Mr. Xu Hengping as an Executive Director of the sixth session of the Board of Directors of the Company.
9.To consider and approve the election of Mr. Xu Haifeng as an Executive Director of the sixth session of the Board of Directors of the Company.
10.To consider and approve the election of Mr. Yuan Changqing as a Non-executive Director of the sixth session of the Board of Directors of the Company.
11.To consider and approve the election of Mr. Liu Huimin as a Non-executive Director of the sixth session of the Board of Directors of the Company.
12.To consider and approve the election of Mr. Yin Zhaojun as a Non-executive Director of the sixth session of the Board of Directors of the Company.
13.To consider and approve the election of Mr. Su Hengxuan as a Non-executive Director of the sixth session of the Board of Directors of the Company.
14.To consider and approve the election of Mr. Chang Tso Tung Stephen as an Independent Director of the sixth session of the Board of Directors of the Company.
15.To consider and approve the election of Mr. Robinson Drake Pike as an Independent Director of the sixth session of the Board of Directors of the Company.
16.To consider and approve the election of Mr. Tang Xin as an Independent Director of the sixth session of the Board of Directors of the Company.
17.To consider and approve the election of Ms. Leung Oi-Sie Elsie as an Independent Director of the sixth session of the Board of Directors of the Company.
18.To consider and approve the election of Mr. Jia Yuzeng as a Non-employee Representative Supervisor of the sixth session of the Supervisory Committee of the Company.
19.To consider and approve the election of Mr. Shi Xiangming as a Non-employee Representative Supervisor of the sixth session of the Supervisory Committee of the Company.
20.To consider and approve the election of Mr. Luo Zhaohui as a Non-employee Representative Supervisor of the sixth session of the Supervisory Committee of the Company.
21.To consider and approve the remuneration of auditors of the Company for the year 2017 and the appointment of auditors of the Company for the year 2018.
SPECIAL RESOLUTION
22.To authorize the Board of Directors to determine if the Company shall issue overseas listed foreign shares (“H Shares”), after taking into account the market conditions and the needs of the Company, of an amount of not more than 20% of the H Shares of the Company in issue as at the date of passing of the special resolution at the Annual General Meeting.
TO RECEIVE RELEVANT REPORTS
23.To receive the duty report of the Independent Directors of the Board of Directors of the Company for the year 2017.
24.To receive the report on the status of connected transactions and the execution of connected transactions management system of the Company for the year 2017.
|
| 2017-11-02 |
股东大会：
将于2017-12-20召开股东大会
会议内容 ▼▲
- ORDINARY RESOLUTIONS
1.To consider and approve the election of Mr. Yuan Changqing as a Non-executive Director of the fifth session of the Board of Directors of the Company.
2.To consider and approve the election of Mr. Luo Zhaohui as a Non-employee Representative Supervisor of the fifth session of the Supervisory Committee of the Company.
|
| 2017-06-12 |
除权日：
美东时间 2017-06-13 每股派息0.14美元
|
| 2017-04-11 |
股东大会：
将于2017-05-31召开股东大会
会议内容 ▼▲
- ORDINARY RESOLUTIONS
1.To consider and approve the report of the Board of Directors of the Company for the year 2016.
2.To consider and approve the report of the Supervisory Committee of the Company for the year 2016.
3.To consider and approve the financial report of the Company for the year 2016.
4.To consider and approve the profit distribution plan of the Company for the year 2016.
5.To consider and approve the remuneration of the Directors and Supervisors of the Company.
6.To consider and approve the election of Mr. Liu Huimin as a Non-executive Director of the fifth session of the Board of Directors of the Company.
7.To consider and approve the election of Mr. Yin Zhaojun as a Non-executive Director of the fifth session of the Board of Directors of the Company.
8.To consider and approve the remuneration of auditors of the Company for the year 2016 and the appointment of auditors of the Company for the year 2017.
9.To consider and approve the Framework Agreement in relation to the Subscription and Redemption of Trust Products and Other Daily Transactions proposed to be entered into between the Company and Chongqing International Trust Inc., the transactions contemplated thereunder and the annual caps for the three years ending 31 December 2019 relating thereto.
10.To consider and approve the Entrusted Investment and Management Agreement for Alternative Investments with Insurance Funds proposed to be entered into between the Company and China Life Investment Holding Company Limited, the transactions contemplated thereunder and the annual caps for the two years ending 31 December 2018 relating thereto.
SPECIAL RESOLUTION
11.To authorize the Board of Directors to determine if the Company shall issue overseas listed foreign shares (“H Shares”) after taking into account the market conditions and the needs of the Company, of an amount of not more than 20% of the H Shares of the Company in issue as at the date of passing of the special resolution at the Annual General Meeting.
Particulars of the authorization include but are not limited to:
(1)To authorize the Board of Directors to allot, issue and deal with H Shares (“New Shares”) in accordance with the Company Law of the PRC and the regulatory requirements of the jurisdictions in which the shares of the Company are listed, after obtaining the approvals of the China Securities Regulatory Commission and other relevant PRC government departments. The aggregate nominal value of the New Shares to be allotted and issued (whether pursuant to a share option or otherwise) shall not exceed 20% of the total nominal value of the H Shares of the Company in issue as at the date of passing of this resolution.
(2)To authorize the Board of Directors to exercise all the powers of the Company to determine the terms and conditions for the allotment and issue of the New Shares, which include the following:
(a)the class and number of the New Shares to be allotted and/or issued;
(b)the target of the issue and the use of proceeds;
(c)the method of determining the issue price of the New Shares and/or the issue price (including the price range);
(d)the commencement and closing dates for the issue;
(e)the class and number of the New Shares to be issued to the existing shareholders;
(f)the making or grant of offers for sale, agreements and options which may require the exercise of such powers.
(3)To authorize the Board of Directors to execute all necessary documents, to complete the necessary formalities and to take other necessary steps in order to complete the allotment, issue and listing of the New Shares, provided that there is no violation of the relevant laws, administrative regulations, the regulatory requirements of the jurisdictions in which the shares of the Company are listed and the Articles of Association of the Company, including but not limited to:
(a)to consider, approve and execute on behalf of the Company agreements in relation to the issue, including but not limited to the underwriting agreement and engagement letters of intermediaries;
(b)to consider, approve and execute on behalf of the Company legal documents in relation to the issue which shall be submitted to the relevant regulatory authorities, and to fulfill the relevant approval processes according to the requirements of the regulatory authorities and the jurisdictions in which the shares of the Company are listed;
(c)to amend the relevant agreements and legal documents mentioned in (a)
(b) above in accordance with the requirements of domestic and foreign regulatory authorities;
(d)to determine the affixing of the company seal on the relevant agreements and legal documents;
(e)to engage intermediaries for the issue, and to approve and to execute all necessary, appropriate, desirable or relevant acts, deeds, documents and other related matters for the issue.
(4)To authorize the Board of Directors to, subject to the approval of the relevant PRC authorities, increase the registered capital of the Company to the required amount according to the actual shareholding structure of the Company at the time of completion of the allotment and issue of the New Shares and in accordance with the Company Law of the PRC.
(5)To authorize the Board of Directors to make amendments to the Articles of Association of the Company as appropriate and necessary upon the allotment and issue of the New Shares, according to the method of the allotment and issue of the New Shares of the Company, the type and number of the New Shares to be allotted and issued, and the actual shareholding structure of the Company at the time of completion of the allotment and issue of the New Shares, in order to reflect the changes in the share capital structure and the registered capital of the Company, and any other changes caused by this authorization.
(6)The general mandate shall come into force as of the date of passing of this resolution at the Annual General Meeting and shall continue in force until the earliest of the following three dates:
(a)the conclusion of the next annual general meeting of the Company;
(b)the expiration of the 12-month period following the passing of this resolution at the Annual General Meeting;
(c)the date on which the authority given under this resolution is revoked or varied by a special resolution of the shareholders of the Company in a general meeting.
TO RECEIVE RELEVANT REPORTS
12.To receive the duty report of the Independent Directors of the Board of Directors of the Company for the year 2016.
13.To receive the report on the status of connected transactions and the execution of connected transactions management system of the Company for the year 2016.
|
| 2016-11-10 |
股东大会：
将于2016-12-27召开股东大会
会议内容 ▼▲
- 1.To consider and approve the outline of the “13th Five-Year” development plan of the Company.
2.To consider and approve the change of the auditor for US Form 20-F of the Company for the year 2016.
3.To consider and approve the Company Framework Agreement (as defined and described in the circular to the shareholders of the Company dated 11 November 2016 (the “Circular”)) and the Pension Company Framework Agreement (as defined and described in the Circular), the transactions contemplated thereunder and the annual caps for the three years ending 31 December 2019 relating thereto.
4.To consider and approve the CLIC Framework Agreement (as defined and described in the Circular) and the CLP&C Framework Agreement (as defined and described in the Circular), the transactions contemplated thereunder and the annual caps for the three years ending 31 December 2019 relating thereto.
5.To consider and approve the renewal of the Framework Agreement for Daily Connected Transactions between the Company and China Guangfa Bank Co., Ltd.
|
| 2016-04-13 |
除权日：
美东时间 2016-06-03 每股派息0.27美元
|
| 2016-04-11 |
股东大会：
将于2016-05-30召开股东大会
会议内容 ▼▲
- ORDINARY RESOLUTIONS
1. To consider and approve the report of the Board of Directors of the Company for the year 2015.
2. To consider and approve the report of the Supervisory Committee of the Company for the year 2015.
3. To consider and approve the financial report of the Company for the year 2015.
4. To consider and approve the profit distribution plan of the Company for the year 2015.
5. To consider and approve the remuneration of the Directors and Supervisors of the Company.
6. To consider and approve the election of Ms. Leung Oi-Sie Elsie as an Independent Director of the fifth session of the Board of Directors of the Company.
7. To consider and approve the remuneration of auditors of the Company for the year 2015.
8. To consider and approve the appointment of auditors of the Company for the year 2016.
9. To consider and approve the Company’s continued donations to China Life Foundation.
10. To consider and approve the proposed amendments to the Procedural Rules for the Board of Directors Meetings, the full text of which is set out in Appendix I to the circular of the Company dated 12 April 2016, and to authorize the Chairman of the Board of Directors or his/her attorney(s) to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time.
SPECIAL RESOLUTION
11. To authorize the Board of Directors to determine if the Company shall issue overseas listed foreign shares (the “H Shares”) after taking into account the market conditions and the needs of the Company, of an amount of not more than 20% of the H Shares of the Company in issue as at the date of passing of the special resolution at the Annual General Meeting.
Particulars of the authorization include but are not limited to:
(1) To authorize the Board of Directors to allot, issue and deal with H Shares (the “New Shares”) in accordance with the Company Law of the PRC and the regulatory requirements of the jurisdictions in which the shares of the Company are listed, after obtaining the approvals of the China Securities Regulatory Commission and other relevant PRC government departments. The aggregate nominal value of the New Shares to be allotted and issued (whether pursuant to a share option or otherwise) shall not exceed 20% of the total nominal value of the H Shares of the Company in issue as at the date of passing of this resolution.
(2) To authorize the Board of Directors to exercise all the powers of the Company to determine the terms and conditions for the allotment and issue of the New Shares, which include the following:
(a) the class and number of the New Shares to be allotted and/or issued;
(b) the target of the issue and the use of proceeds;
(c) the pricing method of the New Shares and/or the issue price (including the price range);
(d) the commencement and closing dates for the issue;
(e) the class and number of the New Shares to be issued to the existing shareholders;
(f) the making or grant of offers for sale, agreements and options which may require the exercise of such powers.
(3) To authorize the Board of Directors to execute all necessary documents, to complete the necessary formalities and to take other necessary steps in order to complete the allotment, issue and listing of the New Shares, provided that there is no violation of the relevant laws, administrative regulations, the regulatory requirements of the jurisdictions in which the shares of the Company are listed and the Articles of Association of the Company, including but not limited to:
(a) to consider, approve and execute on behalf of the Company agreements in relation to the issue, including but not limited to the underwriting agreement and engagement letters of intermediaries;
(b) to consider, approve and execute on behalf of the Company legal documents in relation to the issue which shall be submitted to the relevant regulatory authorities, and to fulfill the relevant approval processes according to the requirements of the regulatory authorities and the jurisdictions in which the shares of the Company are listed;
(c) to amend the relevant agreements and legal documents mentioned in (a) and (b) above in accordance with the requirements of domestic and foreign regulatory authorities;
(d) to determine the affixing of the company seal on the relevant agreements and legal documents;
(e) to engage intermediaries for the issue, and to approve and to execute all necessary, appropriate, desirable or relevant acts, deeds, documents and other related matters for the issue.
(4) To authorize the Board of Directors to, subject to the approval of the relevant PRC authorities, increase the registered capital of the Company to the required amount according to the actual shareholding structure of the Company at the time of completion of the allotment and issue of the New Shares and in accordance with the Company Law of the PRC.
(5) To authorize the Board of Directors to make amendments to the Articles of Association of the Company as appropriate and necessary upon the allotment and issue of the New Shares, according to the method of the allotment and issue of the New Shares of the Company, the type and number of the New Shares to be allotted and issued, and the actual shareholding structure of the Company at the time of completion of the allotment and issue of the New Shares, in order to reflect the changes in the share capital structure and the registered capital of the Company, and any other changes caused by this authorization.
(6) The general mandate shall come into force as of the date of passing of this resolution at the Annual General Meeting and shall continue in force until the earliest of the following three dates:
(a) the conclusion of the next annual general meeting of the Company;
(b) the expiration of the 12-month period following the passing of this resolution at the Annual General Meeting;
(c) the date on which the authority given under this resolution is revoked or varied by a special resolution of the shareholders of the Company in a general meeting.
TO RECEIVE RELEVANT REPORTS
12. To receive the duty report of the Independent Directors of the Board of Directors of the Company for the year 2015.
13. To receive the report on the status of connected transactions and the execution of connected transactions management system of the Company for the year 2015.
|
| 2015-11-12 |
股东大会：
将于2015-12-29召开股东大会
会议内容 ▼▲
- 1.To consider and approve the election of Mr. Tang as an Independent Director of the fifth session of the Board of Directors of the Company.
2.To consider and approve the appointment of auditors of the Company for the year 2016.
3.To consider and approve the entrusted investment and management agreement for alternative investments with insurance funds proposed to be entered into between the Company and China Life Investment Holding Company Limited, the transactions thereunder, the annual cap calculated based on the investment management service fee and performance incentive fee, and the amount of assets to be entrusted for investment and management (including the amount for co-investments).
4.To consider and approve the domestic and overseas multiple issue of debt instruments for replenishment of capital in an aggregate amount of not exceeding RMB80 billion or its equivalent in foreign currency, subject to the Company’s solvency and market conditions. All proceeds from the domestic and overseas issue of such debt instruments for replenishment of capital will, after deduction of the issue expenses, be used to replenish the Company’s capital so as to enhance its solvency.
5.To consider and approve the overseas issue of senior bonds in one or more tranche(s) in an aggregate amount of not exceeding USD3 billion or its equivalent in other foreign currency, subject to the conditions of overseas capital markets. All proceeds from the overseas issue of such senior bonds will, after deduction of the issue expenses, be used in the Company’s overseas investments.
6.To consider and approve the inclusion of “fund sales” in the business scope of the Company. The business scope of the Company set out in its “Legal Person License of Insurance Company” shall be revised as follows: “life insurance, health insurance, accident insurance and other personal insurance; reinsurance of personal insurance; the operation of funds as allowed by laws or regulations or approved by the State Council; various services, consulting and agency businesses relating to personal insurance; fund sales; and other business as approved by the insurance regulatory authority of the PRC.”
|
| 2015-05-28 |
除权日：
美东时间 2015-06-01 每股派息0.33美元
|
| 2015-05-11 |
详情>>
股本变动：
变动后总股本565294.10万股
|
| 2015-05-11 |
详情>>
拆分方案：
每1.0000股拆分成3.0000股
|
| 2015-04-09 |
股东大会：
将于2015-05-28召开股东大会
会议内容 ▼▲
- 1.To consider and approve the report of the Board of Directors of the Company for the year 2014.
2.To consider and approve the report of the Supervisory Committee of the Company for the year 2014.
3.To consider and approve the financial report of the Company for the year 2014.
4.To consider and approve the profit distribution plan of the Company for the year 2014.
5.To consider and approve the remuneration of the Directors and Supervisors of the Company.
6.To consider and approve the remuneration of auditors of the Company for the year 2014 and the appointment of auditors of the Company for the year 2015.
7.To consider and approve the election of Mr. Yang Mingsheng as an Executive Director of the fifth session of the Board of Directors of the Company.
8.To consider and approve the election of Mr. Lin Dairen as an Executive Director of the fifth session of the Board of Directors of the Company.
9.To consider and approve the election of Mr. Xu Hengping as an Executive Director of the fifth session of the Board of Directors of the Company.
10.To consider and approve the election of Mr. Xu Haifeng as an Executive Director of the fifth session of the Board of Directors of the Company.
11.To consider and approve the election of Mr. Miao Jianmin as a Non-executive Director of the fifth session of the Board of Directors of the Company.
12.To consider and approve the election of Mr. Zhang Xiangxian as a Non-executive Director of the fifth session of the Board of Directors of the Company.
13.To consider and approve the election of Mr. Wang Sidong as a Non-executive Director of the fifth session of the Board of Directors of the Company.
14.To consider and approve the election of Mr. Liu Jiade as a Non-executive Director of the fifth session of the Board of Directors of the Company.
15.To consider and approve the election of Mr. Anthony Francis Neoh as an Independent Director of the fifth session of the Board of Directors of the Company.
16.To consider and approve the election of Mr. Chang Tso Tung Stephen as an Independent Director of the fifth session of the Board of Directors of the Company.
17.To consider and approve the election of Mr. Huang Yiping as an Independent Director of the fifth session of the Board of Directors of the Company.
18.To consider and approve the election of Mr. Drake Pike as an Independent Director of the fifth session of the Board of Directors of the Company.
19.To consider and approve the election of Mr. Miao Ping as a Non Employee Representative Supervisor of the fifth session of the Supervisory Committee of the Company.
20.To consider and approve the election of Mr. Shi Xiangming as a Non Employee Representative Supervisor of the fifth session of the Supervisory Committee of the Company.
21.To consider and approve the election of Ms. Xiong Junhong as a Non Employee Representative Supervisor of the fifth session of the Supervisory Committee of the Company.
22.To authorize the Board of Directors to determine if the Company shall issue overseas listed foreign shares (“H Shares”) after taking into account the market conditions and the needs of the Company, of an amount of not more than 20% of the H Shares in issue as at the date of passing of the special resolution at the Annual General Meeting.
Particulars of the authorization include but are not limited to:
(1)To authorize the Board of Directors to allot, issue and deal with H Shares (“New Shares”) in accordance with the Company Law of the PRC and the regulatory requirements of the jurisdictions in which the shares of the Company are listed, after obtaining the approval of the China Securities Regulatory Commission and other relevant PRC government departments. The aggregate nominal value of the New Shares to be allotted and issued (whether pursuant to a share option or otherwise) shall not exceed 20% of the total nominal value of the H Shares of the Company in issue as at the date of passing of this resolution.
(2)To authorize the Board of Directors to exercise all the powers of the Company, to determine the terms and conditions for the allotment and issue of the New Shares, which include the following:
(a) the class and number of the New Shares to be allotted and/or issued;
(b) the target of the issue and the use of proceeds;
(c) the method of determining the issue price of the New Shares and/or the issue price (including the price range);
(d) the commencement and closing dates for the issue;
(e) the class and number of the New Shares to be issued to existing shareholders;
(f) the making or grant of offers for sale, agreements and options which may require the exercise of such powers.
(3) To authorize the Board of Directors to execute all necessary documents, to complete the necessary formalities and to take other necessary steps in order to complete the allotment, issue and listing of the New Shares, provided that there is no violation of the relevant laws, administrative regulations, the regulatory requirements of the jurisdictions in which the shares of the Company are listed and the Articles of Association of the Company, including but not limited to:
(a) to consider, approve and execute on behalf of the Company agreements in relation to the issue, including but not limited to the underwriting agreement and engagement letters of intermediaries;
(b)to consider, approve and execute on behalf of the Company legal documents in relation to the issue which shall be submitted to the relevant regulatory authorities, and to fulfill the relevant approval processes according to the requirements of the regulatory authorities and the jurisdictions in which the shares of the Company are listed;
(c) to amend the relevant agreements and legal documents mentioned in (a) and (b) above in accordance with the domestic and foreign regulatory authorities;
(d) to determine the affixing of the company seal on the relevant agreements and legal documents;
(e) to engage intermediaries for the issue, and to approve and to execute all necessary, appropriate, desirable or relevant acts, deeds, documents and other related matters.
(4)To authorize the Board of Directors to, subject to the approval of the relevant PRC authorities, increase the registered capital of the Company to the required amount according to the actual shareholding structure of the Company at the time of completion of the allotment and issue of the New Shares and in accordance with the Company Law of the PRC.
(5)To authorize the Board of Directors to make amendments to the Articles of Association of the Company as appropriate and necessary upon the allotment and issue of the New Shares according to the method of the allotment and issue of the New Shares of the Company, the type and number of the New Shares to be allotted and issued, and the actual shareholding structure of the Company at the time of completion of the allotment and issue of the New Shares, in order to reflect the changes in the share capital structure, the registered capital and any other changes caused by this authorization.
(6)The general mandate shall come into force as of the date of passing of this resolution at the Annual General Meeting and shall continue in force until the earliest of the following three dates:
(a) the conclusion of the next annual general meeting of the Company;
(b) the expiration of the 12-month period following the passing of this resolution at the Annual General Meeting;
(c) the date on which the authority given under this resolution is revoked or varied by a special resolution of the shareholders of the Company in a general meeting.
23. To consider and approve the overseas issue of debt instruments for replenishment of capital in an amount of not exceeding RMB3 billion subject to the approval of regulatory authorities and based on the market conditions. All proceeds from the overseas issue of such debt instruments for replenishment of capital will, after deduction of the issue expenses, be used to replenish the Company’s capital so as to enhance its solvency.
To authorize the Board of Directors to delegate the management of the Company to deal with and decide on all specific matters relating to the overseas issue of debt instruments for replenishment of capital subject to the approval of regulatory authorities and based on the market conditions. Such authorization shall include but not limited to the following:
(1)submitting to, filing with and obtaining approvals and consents from the relevant domestic or overseas governmental departments and/or regulatory authorities;
(2)executing, implementing, revising, supplementing, completing, delivering and issuing all relevant agreements, contracts and documents (including, without limitation, announcements, circulars, sponsorship, underwriting agreements and contracts for intermediary service, etc.) in connection with the overseas issue of debt instruments for replenishment of capital to the relevant domestic and overseas regulatory authorities, stock exchanges, organizations and/or individuals;
(3)formulating and implementing a detailed proposal with respect to the overseas issue of debt instruments for replenishment of capital, including, without limitation, the type of the issue, the size of the issue, the form of the issue, the timing of the issue, the tranches, the terms and conditions of the issue, the term of the debts, the coupon rate, the registration of such overseas debt instruments for custody purpose, the measures for the administration of overseas debt instruments for replenishment of capital and investment guideline, and after taking into account the actual circumstances, market conditions, policy changes and opinions from regulatory departments and domestic and overseas stock exchanges, making necessary changes to the overseas issue of debt instruments for replenishment of capital and determining the timing of the issue;
(4)the authorization for the overseas issue of debt instruments for replenishment of capital will be valid for 24 months from the date of approval by the shareholders’ general meeting.
24.To receive the duty report of the Independent Directors of the fourth session of the Board of Directors of the Company for the year 2014.
25.To receive the report on the status of connected transactions and the execution of connected transactions management system of the Company for the year 2014.
|
| 2014-11-12 |
股东大会：
将于2014-12-29召开股东大会
会议内容 ▼▲
- 1. To consider and approve the entrusted investment and management agreement for alternative investments with insurance funds proposed to be entered into between the Company and China Life Investment Holding Company Limited, the transactions thereunder, the annual cap calculated based on the investment management service fee and performance incentive fee, and the amount of assets to be entrusted for investment and management (including the amount for co-investments).
|
| 2014-05-13 |
股东大会：
将于2014-05-29召开股东大会
会议内容 ▼▲
- 1. To consider and approve the report of the Board of Directors of the Company for the year 2013.
2. To consider and approve the report of the Supervisory Committee of the Company for the year 2013.
3. To consider and approve the financial report of the Company for the year 2013.
4. To consider and approve the profit distribution plan of the Company for the year 2013.
5. To consider and approve the remuneration of the Directors and Supervisors of the Company.
6. To consider and approve the appointment of the auditors of the Company for the year 2014.
7. To consider and approve the election of Mr. Su Hengxuan as the Executive Director of the fourth session of the Board of Directors of the Company.
8. To consider and approve the election of Mr. Miao Ping as the Executive Director of the fourth session of the Board of Directors of the Company.
9. To consider and approve the cap amounts in respect of the Framework Agreement for Daily Connected Transactions between the Company and China Guangfa Bank Co., Ltd.
10. To consider and approve the capital injection by the Company to China Life Property and Casualty Insurance Company Limited.
11. To authorise the Board of Directors to determine if the Company shall issue overseas listed foreign shares (“H Shares”) after taking into account the market conditions and the needs of the Company, of an amount of not more than 20% of the H Shares in issue as at the date of passing of the special resolution at the Annual General Meeting.
12. To consider and approve the extension of the validity period of the resolution on the issue of subordinated debt financing instruments outside the PRC.
13. To receive the duty report of the Independent Directors of the fourth session of the Board of Directors of the Company for the year 2013.
14. To receive the report on the status of connected transactions and the execution of connected transactions management system of the Company for the year 2013.
15. To consider and approve the Company Framework Agreement (as defined and described in the circular to the shareholders of the Company dated 13 May 2014 (the “Circular”)) and the Pension Company Framework Agreement (as defined and described in the Circular), the transactions contemplated thereunder and the annual caps for the three years ending 31 December 2016 relating thereto.
16. To consider and approve the CLIC Framework Agreement (as defined and described in the Circular) and the P&C Company Framework Agreement (as defined and described in the Circular), the transactions contemplated thereunder and the annual caps for the three years ending 31 December 2016 relating thereto.
17. To consider and approve the following proposed amendments to the Articles of Association, and to authorize the Chairman of the Board of Directors or his/her attorney(s) to make such further amendments which in his/her opinion may be necessary or desirable in the process of obtaining the relevant regulatory approvals in accordance with the requirements of relevant regulatory bodies and the stock exchanges on which the Company is listed from time to time. The amended Articles of Association shall come into effect only after the relevant approvals from the China Insurance Regulatory Commission are obtained.
|
| 2014-03-27 |
除权日：
美东时间 2014-05-30 每股派息0.73美元
|
| 2013-06-05 |
除权日：
美东时间 2013-06-05 每股派息0.34美元
|
| 2013-03-11 |
复牌提示：
2013-03-11 09:23:18 停牌，复牌日期 2013-03-12 09:32:42
|
| 2012-05-22 |
除权日：
美东时间 2012-05-22 每股派息0.55美元
|
| 2011-06-03 |
除权日：
美东时间 2011-04-26 每股派息0.92美元
|